trial · primary record
Zanzalintinib
Pancreatic Neuroendocrine Tumor (pNET)
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 440 |
| Primary completion | 2029-06-30 |
| Primary endpoint | Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) |
| Registry ID | NCT06943755 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:28:12.058Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06943755
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.